Gaucher Disease

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by glucocerebrosidase deficiency, leading to glucocerebroside accumulation in macrophages (Gaucher cells with "crinkled tissue paper" cytoplasm). Type 1 (non-neuronopathic) accounts for 95% of cases and is most common in Ashkenazi Jewish populations (1:800 prevalence). Key orthopaedic manifestations include bone crises (severe pain and fever mimicking osteomyelitis but culture-negative—do NOT treat with antibiotics), AVN of the hip and shoulder, pathological fractures, and Erlenmeyer flask deformity (failure of distal femur metaphyseal remodeling). Enzyme replacement therapy (ERT) with imiglucerase has transformed outcomes and is first-line treatment.

Gaucher disease is the most common lysosomal storage disorder.

Prevalence:

• General population: 1 in 40,000-60,000
• Ashkenazi Jewish population: approximately 1 in 800 (carrier frequency around 1:15)
• In the ICGG Gaucher Registry (1698 patients, 38 countries), 94% had type 1, fewer than 1% type 2, and 5% type 3

Genetics:

• Autosomal recessive inheritance
• GBA gene mutation (chromosome 1q21)
• Encodes glucocerebrosidase (acid beta-glucosidase)
• Over 400 mutations identified
• Most common alleles in the Registry: N370S (53%), L444P (18%), 84GG (7%), IVS2+1 (2%)
• N370S is associated with the type 1 (non-neuronopathic) phenotype; L444P homozygosity is associated with more severe, often neuronopathic disease
• Genotype influences age at diagnosis (mean 27 years for N370S/N370S vs around 2 years for L444P/L444P)

Mechanism:

• Glucocerebrosidase deficiency → glucocerebroside (glucosylceramide) cannot be degraded
• Substrate accumulates within macrophages, forming Gaucher cells
• Gaucher cells infiltrate bone marrow, spleen, liver, and lymph nodes

Gaucher Cells:

• Macrophages engorged with glucocerebroside
• "Crinkled tissue paper" or "wrinkled silk" cytoplasm
• Found in bone marrow, spleen, liver, lymph nodes
• Histiocytes 20-100 microns in diameter

Mechanism of Bone Disease:

1. Marrow Infiltration

   • Gaucher cells replace normal marrow
   • Decreased hematopoiesis → cytopenias
   • Marrow expansion → cortical thinning

2. Vascular Compromise

   • Marrow infiltration → ischemia
   • Bone infarcts and bone crises
   • AVN of femoral head, humeral head

3. Bone Remodeling Failure

   • Interference with osteoclast/osteoblast function
   • Failed metaphyseal remodeling → Erlenmeyer flask
   • Osteopenia and pathological fractures

Type 1 (Non-neuronopathic):

• 95% of Gaucher patients
• No primary neurological involvement
• Variable severity - some diagnosed in adulthood
• Significant bone disease
• Excellent response to ERT

Type 2 (Acute neuronopathic):

• Presentation in infancy (under 2 years)
• Severe neurological deterioration
• Brainstem dysfunction, seizures
• Death usually by 2-3 years
• ERT does not cross blood-brain barrier

Type 3 (Chronic neuronopathic):

• Childhood presentation
• Slower neurological progression than Type 2
• Bone and visceral disease similar to Type 1
• ERT helps visceral disease, not neurological

Bone Crises (Acute):

• Severe bone pain, often femur or tibia
• Fever, malaise
• Elevated ESR, CRP
• Mimics osteomyelitis - critical differential
• Caused by acute marrow ischemia/infarction
• May last days to weeks
• Treatment: analgesia, hydration, steroids

Avascular Necrosis:

• Femoral head most common (40% of Type 1)
• Humeral head also affected
• Chronic marrow infiltration → vascular compromise
• May progress despite ERT if established
• Often requires arthroplasty

Erlenmeyer Flask Deformity:

• Failure of metaphyseal remodeling
• Classic at distal femur
• Wide metaphysis, narrow diaphysis
• "Flask" shape on X-ray
• Bilateral and symmetric
• Does not cause symptoms directly

Pathological Fractures:

• Osteopenia from marrow expansion
• Cortical thinning
• Vertebral compression fractures
• Long bone fractures (often minimal trauma)
• Healing may be delayed

Other Bone Features:

• Bone infarcts (medullary)
• Osteonecrosis of vertebrae
• Growth retardation in children
• Chronic bone pain

Hematological:

• Anemia (Gaucher cell marrow replacement)
• Thrombocytopenia (splenic sequestration)
• Bleeding tendency (both platelet and coagulation defects)
• Leukopenia (less common)

Hepatosplenomegaly:

• Massive splenomegaly (25x normal)
• Hepatomegaly (2-3x normal)
• Hypersplenism → cytopenias
• May cause abdominal discomfort

Other:

• Growth retardation
• Delayed puberty
• Pulmonary involvement (rare)
• Increased malignancy risk (myeloma, lymphoma)

Definitive Diagnosis:

• Glucocerebrosidase enzyme activity (leukocytes or fibroblasts)
  • Under 15% of normal is diagnostic
• Genetic testing - GBA gene mutations
  • Confirms diagnosis
  • Allows family screening

Laboratory:

• Chitotriosidase: Markedly elevated (biomarker)
• Acid phosphatase: Elevated
• Ferritin: Elevated
• CBC: Anemia, thrombocytopenia
• Coagulation: May be abnormal

Imaging:

• Plain X-rays: Erlenmeyer flask, osteopenia, lytic lesions
• MRI: Gold standard for bone assessment
  • T1: Low signal (fatty marrow replacement)
  • Bone marrow burden score
  • AVN detection
  • Bone infarcts
• CT: Hepatosplenomegaly assessment
• DXA: Bone mineral density

MRI Bone Marrow Burden Score:

• Quantifies severity of marrow infiltration
• Used to monitor treatment response
• Correlates with risk of bone complications

Severity Scoring:

Interpretation:

• Used to guide treatment intensity
• Monitor response to ERT
• Predict fracture risk

AVN Management:

1. Early AVN (Pre-collapse):

   • Core decompression
   • Limited evidence in Gaucher-related AVN
   • May slow progression
   • Coordinate with hematology

2. Advanced AVN (Collapse/Arthritis):

   • Total hip arthroplasty
   • Total shoulder arthroplasty
   • Higher complication rate than primary OA
   • Increased bleeding risk

THA Considerations:

• Platelet transfusion may be needed (target greater than 50,000)
• Cement may be preferable (poor bone quality)
• Extended prophylaxis (increased VTE risk)
• Consider tranexamic acid
• Liaise with hematology pre-operatively

Pathological Fractures:

• Surgical fixation when indicated
• Delayed healing expected
• May require bone grafting
• Internal fixation may be challenging (soft bone)

Splenectomy:

• Rarely needed with ERT
• May worsen bone disease (increased bone marrow infiltration)
• Only for massive, symptomatic splenomegaly
• Partial splenectomy preferred

Skeletal:

• Progressive AVN requiring arthroplasty
• Chronic bone pain
• Multiple pathological fractures
• Vertebral collapse
• Growth retardation

Hematological:

• Severe anemia requiring transfusion
• Bleeding complications
• Hypersplenism

Other:

• Pulmonary hypertension
• Increased malignancy risk (myeloma, lymphoma)
• Parkinsonism (associated with GBA mutations, including heterozygotes)

Surgery-Specific Complications (and Prevention):

• Increased bleeding (platelet and coagulation defects) → pre-operative hematology consultation, platelet transfusion if needed, meticulous hemostasis, consider tranexamic acid
• Delayed bone healing → protected weight bearing, longer follow-up
• Higher infection risk → standard prophylaxis, vigilance
• Implant loosening (poor bone quality) → consider cement fixation
• Prolonged recovery → optimise ERT dosing perioperatively

ERT Era Outcomes:

• Life expectancy near-normal for Type 1
• Dramatic reduction in splenectomy rates
• Prevention of new bone complications
• Quality of life greatly improved

Bone Disease Outcomes:

• Established AVN often progresses despite ERT
• New bone crises reduced on ERT
• Bone density improves slowly
• Pathological fractures less common with treatment

Arthroplasty Outcomes:

• Good functional results
• Higher complication rate than primary OA
• May need earlier revision
• Coordinate perioperative care with hematology

Global Epidemiology:

• Pan-ethnic but markedly enriched in Ashkenazi Jewish populations (carrier frequency around 1:15; affected approximately 1:800)
• General population prevalence approximately 1:40,000 to 1:60,000
• The international ICGG Gaucher Registry remains the largest natural-history dataset; many countries maintain national registries to monitor long-term treatment outcomes

Side-by-Side Guidance:

Registry and Therapy Access:

• Imiglucerase, velaglucerase alfa, and taliglucerase alfa (ERT) and eliglustat / miglustat (SRT) are high-cost orphan drugs; most health systems restrict access to confirmed disease prescribed through specialist metabolic services
• High-resource settings: ready access to ERT/SRT, MRI monitoring, and multidisciplinary metabolic-orthopaedic-haematology teams
• Limited-resource settings: diagnosis may be delayed; ERT access constrained by cost; greater reliance on supportive care, with higher rates of advanced AVN and splenectomy

Orthopaedic Principle (universal):

• Patients requiring joint replacement, fracture fixation, or spinal surgery must be co-managed with haematology and metabolic medicine, with perioperative platelet and bleeding-risk optimisation